Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive Disorder

Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569 Dierickx, 2013, Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors, Leuk Lymphoma, 54, 2433, 10.3109/10428194.2013.780655 Quinlan, 2011, Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States, Am J Hematol, 86, 206, 10.1002/ajh.21911 Sampaio, 2012, Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database, Transplantation, 94, 990, 10.1097/TP.0b013e318270bc7b Ibrahim, 2012, Post-transplant lymphoproliferative disorders, Adv Haematol, 10.1155/2012/230173 Al-Mansour, 2013, Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies, Curr Hematol Malig Rep, 8, 173, 10.1007/s11899-013-0162-5 Luskin, 2015, The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder, Am J Transplant, 15, 2665, 10.1111/ajt.13324 Bishnoi, 2017, Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients, Exp Hematol Oncol, 6, 26, 10.1186/s40164-017-0087-0 Koff, 2018, Impact of the posttransplant lymphoproliferative disorder subtype on survival, Cancer, 124, 2327, 10.1002/cncr.31339 Izadi, 2012, Bone marrow involvement by lymphoproliferative disorders after renal transplantation: PTLD. Int. Survey, J Cancer Res Ther, 8, 62, 10.4103/0973-1482.95176 DeStefano, 2018, Management of post-transplant lymphoproliferative disorders, Br J Haematol, 180, 330, 10.1111/bjh.15263 Evens, 2010, Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era, J Clin Oncol, 28, 1038, 10.1200/JCO.2009.25.4961 Preiksaitis, 2004, New developments in the diagnosis and management of post-transplantation lymphoproliferative disorders in solid organ transplant recipients, Clinical Inf Dis, 39, 1016, 10.1086/424447 Reshef, 2011, Reduction of immunosuppression as initial therapy for post-transplantation lymphoproliferative disorder, Am J Transplant, 11, 336, 10.1111/j.1600-6143.2010.03387.x Ghobrial, 2005, Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era, Leukemia Lymphoma, 46, 191, 10.1080/10428190400012011 Trappe, 2016, Response to rituximab induction is a predictive marker in B-cell post transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter, phase II trial, J Clin Oncol, 35, 536, 10.1200/JCO.2016.69.3564 Elstrom, 2006, Treatment of PTLD with Rituximab or chemotherapy, Am J Transplant, 6, 569, 10.1111/j.1600-6143.2005.01211.x Svoboda, 2006, Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab, Transplant Int, 19, 259, 10.1111/j.1432-2277.2006.00284.x Oertel, 2003, Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carbiplatin and etoposide, Br J Haematol, 123, 830, 10.1046/j.1365-2141.2003.04705.x Zimmermann, 2011, Therapeutic options in post-transplant lymphoproliferative disorders, Ther Adv Hematol, 2, 393, 10.1177/2040620711412417 Opelz, 2004, Lymphomas after solid organ transplantation: a collaborative transplant study report, Am J Transplant, 4, 222, 10.1046/j.1600-6143.2003.00325.x Kesavan, 2019, Front-line treatment of high grade B cell non-hodgkin lymphoma, Curr Hematol Malig Rep, 14, 207, 10.1007/s11899-019-00518-8 Taylor, 2015, Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients, Nephrol Dial Transplant, 30, 1774, 10.1093/ndt/gfv260